FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- National Weather Service to evaluate work after missed call on storm
- Blizzard howls its way into Boston but largely spares NYC
- Pittsburgh travelers feel effects of Northeast blizzard
- Medicare payments to tie doctor, hospital payments to quality rather than volume of care
- Ramping up e-cigarette voltage may be more hazardous to health
- 3 Russians charged with spying spoke in code, passed concealed message, sought recruits, federal prosecutor alleges
- VA plans major structure changes; Pittsburgh’s fate as regional HQ remains unclear
- Dems stall Keystone XL legislation
- $100 bill leads to $100M lottery win in Massachusetts
- Ex-CIA officer convicted of leaking info about covert Iran mission
- American drone hit kills al-Qaida terror suspects in Yemen